Key Highlights

  • 13.42% was the gain for Neurocrine Biosciences (NASDAQ:NBIX) on November 3, 2026, after third-quarter Revenue rose 41% to USD 1,123 million from USD 795 million.
  • USD 801 million of Ingrezza net sales, up 17% from USD 687 million, with 2026 Ingrezza guidance raised to USD 2,900 million to USD 2,925 million from USD 2,825 million to USD 2,875 million.
  • USD 211 million of Crenessity net sales, up 115% from USD 98 million a year earlier, as the congenital adrenal hyperplasia drug continues its launch.
  • USD 3.29 of non-GAAP diluted Earnings a share, up from USD 2.17, against GAAP diluted earnings of USD 1.96, down from USD 2.04 a year earlier.

What Neurocrine Reported

Neurocrine Biosciences reported third-quarter 2026 results for the quarter ended September 30. Total revenue was USD 1,123 million, up 41%. Ingrezza, the company's treatment for tardive dyskinesia and chorea in Huntington's disease, produced USD 801 million of net sales, up 17%. Crenessity, approved for classic congenital adrenal hyperplasia, a genetic disorder of the adrenal glands, produced USD 211 million, up 115%. Non-GAAP diluted earnings were USD 3.29 a share against USD 2.17, while GAAP earnings were USD 1.96 against USD 2.04. The shares closed up 13.42% on November 3, 2026, according to published market data. Ingrezza made up about 71% of revenue and Crenessity about 19% (simple arithmetic), leaving about USD 111 million from other sources. Non-GAAP earnings rose about 52% (simple arithmetic), faster than revenue, which shows Operating Leverage on a larger sales base at Neurocrine Biosciences (NASDAQ:NBIX).

Why the Guidance Raise Matters

Guidance resets the base on which investors value a drug maker. Neurocrine raised its 2026 Ingrezza net sales range to USD 2,900 million to USD 2,925 million from USD 2,825 million to USD 2,875 million, a midpoint increase of about USD 62.5 million (simple arithmetic). The release gives no 2026 guidance for Crenessity, so investors must estimate the launch curve themselves. The gap between non-GAAP and GAAP earnings, USD 1.33 a share this quarter (simple arithmetic), reflects items such as Stock Compensation and other adjustments, so the cleaner figure for comparison with consensus depends on which basis analysts use. The raise also tells investors that Demand for Ingrezza held up through the third quarter despite its larger base.

Risks and What to Watch Next

Ingrezza growth of 17% is slower than the company-wide 41%, and the drug faces pricing pressure from payers and the prospect of competition. Crenessity depends on a small patient population, so launch growth can slow once early patients are treated. GAAP earnings fell year over year even as revenue rose, which shows costs are climbing. A 13.4% single-day gain also raises the bar for the next report, and concentration in two products means any setback in either one would matter. Investors will watch Crenessity prescriptions, Ingrezza demand, research spending and any pipeline readouts from the company. The release did not give a 2026 Crenessity range, so analysts will rely on quarterly trends, and a surprise in either direction could move the shares sharply again.

Where Things Stand

Neurocrine rose 13.4% because it beat on revenue growth, raised Ingrezza guidance and showed a second product, Crenessity, scaling quickly. Growth is concentrated in two drugs, and GAAP earnings were lower than a year ago, so the picture is strong but not risk-free. For Neurocrine Biosciences (NASDAQ:NBIX), the next catalysts are Crenessity launch data and any pricing changes affecting Ingrezza. A large one-day gain can fade. Nothing here is Investment advice or a price forecast.